Lilly sets $50 Medicare cap for Zepbound and Mounjaro as CMS details BALANCE
Washington published new BALANCE program details and Lilly named its prices, but the $50 monthly Medicare cap applies only if a patient's Part D plan takes part.
The federal government released more of the fine print on March 9, 2026 for a program meant to lower what Medicare and Medicaid enrollees pay for weight-loss GLP-1 drugs, and Eli Lilly named the terms it will offer on three of its products [1][2].
Lilly said its tirzepatide brands, Zepbound and Mounjaro, plus orforglipron, a pill that is not yet approved, would be sold through Medicare Part D plans that sign up for the model starting January 1, 2027. For most people in those plans, the company said monthly out-of-pocket costs would top out at $50 once a deductible is met. Until that deductible is reached, patients would pay no more than $245 a month plus a dispensing fee [1].
Lilly cautioned that the $50 ceiling is not universal. The company said "the majority of Medicare plan options will honor the $50 out-of-pocket cap," while a small number of basic Part D plans will charge differently [1]. It added that it would inform patients and doctors about plan choices and about "smoothing programs" that spread costs across the year [1].
CMS describes BALANCE - short for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth - as a voluntary arrangement in which the agency bargains over prices and coverage rules with drugmakers on behalf of state Medicaid agencies and Part D sponsors [2]. Manufacturers, states and plans each decide whether to take part [2].
The drug list CMS published includes every formulation of Mounjaro, Ozempic, Rybelsus and Wegovy, the KwikPen version of Zepbound, and Foundayo (orforglipron), for both their existing approvals, such as type 2 diabetes, and for weight management [2]. Ozempic, Rybelsus and Wegovy contain semaglutide. To qualify, CMS says a product must show average weight loss of at least 9.5% at an FDA-approved dose in a randomized trial [2].
The two organizations describe the Medicare timeline differently. Lilly said its drugs would arrive in Part D plans under BALANCE beginning January 1, 2027 [1]. CMS said BALANCE is not launching in Medicare in 2027, and that older adults will instead use the separate Medicare GLP-1 Bridge demonstration, which the agency extended through December 31, 2027 so it can gather data on GLP-1 use before BALANCE might begin in Part D [2]. Lilly said the Bridge offers Zepbound and orforglipron, if approved, at no more than $50 a month with no deductible from July 1 through December 31, 2026 [1]; CMS lists the Bridge as running from July 1, 2026 to December 31, 2027 [2].
On Medicaid, Lilly said state programs can apply starting May 1, 2026, with rolling entry [1], while CMS gives a window of May 2026 through January 1, 2027 [2]. CMS says access depends on which manufacturers and states join, and that patients would face conditions set in negotiations, including prior authorization requirements, so the model "will not guarantee coverage for any individual" [2]. Medicaid enrollees who get GLP-1s for weight management under the model also receive a lifestyle support program paid for by the manufacturer [2].
Which other manufacturers will take part, and what they will charge patients, has not been disclosed.
Why it matters for patients
Medicare and Medicaid generally do not pay for GLP-1s prescribed for weight loss, and CMS points to the drugs' cost as the reason [2]. The figures released this week are an early indication of what an eligible enrollee might owe, but they apply only inside the program.
Several details shape that picture. What a patient pays depends on which plan they are in, not only which drug they take; Lilly says a small share of Part D plans will charge more than $50 [1]. Medicaid coverage is not automatic and can hinge on state and manufacturer decisions plus prior authorization rules [2]. And because CMS says the model guarantees coverage for no individual [2], holding Medicare or Medicaid coverage does not by itself settle whether a GLP-1 is covered or what it costs.
What happens next
- May 1, 2026: state Medicaid agencies may begin applying to BALANCE, with a rolling start [1]; CMS sets the window as May 2026 to January 1, 2027 [2].
- July 1, 2026: the Medicare GLP-1 Bridge is set to begin [1][2].
- January 1, 2027: Lilly says BALANCE coverage of its drugs starts in Part D [1]; CMS says BALANCE is not launching in Medicare that year [2].
- December 31, 2027: the Bridge is scheduled to end, according to CMS [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.